Daily Endocrinology Research Analysis
Three mechanistic studies advanced endocrine science today: a Nature paper maps an amygdala-to-liver circuit that controls stress hyperglycaemia, a JCI Insight study shows how maternal thyroxine (T4) drives human fetal neurogenesis via cell-intrinsic T4→T3 activation, and a Diabetes paper reveals iNOS/NO-mediated mitochondrial inhibition causing β cell–specific Golgi disruption in type 1 diabetes pathogenesis.
Summary
Three mechanistic studies advanced endocrine science today: a Nature paper maps an amygdala-to-liver circuit that controls stress hyperglycaemia, a JCI Insight study shows how maternal thyroxine (T4) drives human fetal neurogenesis via cell-intrinsic T4→T3 activation, and a Diabetes paper reveals iNOS/NO-mediated mitochondrial inhibition causing β cell–specific Golgi disruption in type 1 diabetes pathogenesis.
Research Themes
- Neuroendocrine control of glucose during stress
- Maternal thyroid hormone and fetal brain development
- Inflammation–mitochondria–Golgi axis in β-cell dysfunction in type 1 diabetes
Selected Articles
1. Amygdala-liver signalling orchestrates glycaemic responses to stress.
This study delineates a neural–humoral pathway from the amygdala to the liver that acutely regulates blood glucose in response to stress. Using multimodal experiments, the authors show that amygdala-driven signaling orchestrates hepatic glucose output, defining a mechanistic basis for stress hyperglycaemia.
Impact: Revealing a brain–liver circuit for stress glycaemia reframes neuroendocrine control of metabolism and opens therapeutic avenues for stress-exacerbated hyperglycaemia.
Clinical Implications: Targets within the amygdala–liver axis could be leveraged to blunt stress-induced hyperglycaemia in diabetes and critical illness, complementing peripheral glucose-lowering therapies.
Key Findings
- Identifies an amygdala-to-liver signaling pathway that regulates hepatic glucose output during stress.
- Demonstrates that neural control from the amygdala orchestrates systemic glycaemic responses.
- Provides mechanistic insight into stress hyperglycaemia beyond peripheral hormonal changes.
Methodological Strengths
- Multimodal mechanistic approach integrating neural manipulation and metabolic readouts.
- High-rigor experimental design published in a top-tier journal, suggesting robust validation.
Limitations
- Preclinical model limits immediate translation to humans.
- Abstracted details on specific molecular mediators are not provided in the summary text.
Future Directions: Define molecular effectors linking amygdala activity to hepatic glucose metabolism and test translatability in human neuroimaging and interventional studies.
Behavioural adaptations to environmental threats are crucial for survival
2. Thyroid hormone promotes fetal neurogenesis.
Using patient-derived MCT8-deficient iPSCs, cerebral organoids, and multi-omic profiling, the authors show that T4, via transient DIO2-mediated intracellular conversion to T3 and coordinated receptor expression, programs human neural precursor cells toward neurogenesis. These data mechanistically link maternal thyroid hormone sufficiency to proper fetal cortical development.
Impact: Defines a cell-intrinsic T4 activation program essential for human fetal neurogenesis, providing mechanistic justification for optimizing maternal thyroid hormone in early pregnancy.
Clinical Implications: Supports vigilant screening and timely levothyroxine treatment of maternal hypothyroidism and hypothyroxinemia in early pregnancy to safeguard fetal neurodevelopment.
Key Findings
- T4 drives transcriptional programs that advance human neural precursor cells along dorsal projection neurogenesis trajectories.
- Optimal thyroid hormone levels are necessary for neuronal differentiation in MCT8-deficient cerebral organoids and neural precursor cultures.
- Transient intracellular activation of T4 via DIO2-mediated T3 conversion and receptor expression coordinates cell division mode and cell cycle progression.
Methodological Strengths
- Use of patient-derived iPSCs, cerebral organoids, and single-cell, spatial, and bulk transcriptomics.
- Mechanistic dissection of intracellular thyroid hormone activation (DIO2) and receptor signaling.
Limitations
- Preclinical models (organoids and cell cultures) may not capture full in vivo complexity.
- Clinical intervention thresholds and dosing implications were not tested.
Future Directions: Prospective clinical studies correlating early gestational thyroid status and neurodevelopment with biomarkers of intracerebral T4→T3 activation; evaluation of timing/dose of levothyroxine.
Maternal low thyroxine (T4) serum levels during the first trimester of pregnancy correlate with cerebral cortex volume and mental development of the progeny, but why neural cells during early fetal brain development are vulnerable to maternal T4 levels remains unknown. In this study, using iPSCs obtained from a boy with a loss-of-function mutation in MCT8 - a transporter previously identified as critical for thyroid hormone uptake and action in neural cells - we demonstrate that thyroid hormone induces transcriptional changes that promote the progression of human neural precursor cells along the dorsal projection trajectory. Consistent with these findings, single-cell, spatial, and bulk transcriptomics from MCT8-deficient cerebral organoids and cultures of human neural precursor cells underscored the necessity for optimal thyroid hormone levels for these cells to differentiate into neurons. The controlled intracellular activation of T4 signaling occurs through the transient expression of the enzyme type 2 deiodinase, which converts T4 into its active form, T3, alongside the coordinated expression of thyroid hormone nuclear receptors. The intracellular activation of T4 in neural precursor cells results in transcriptional changes important for their division mode and cell cycle progression. Thus, T4 is essential for fetal neurogenesis, highlighting the importance of adequate treatment for mothers with hypothyroidism.
3. Proinflammatory Cytokines Mediate Pancreatic β-Cell-Specific Alterations to Golgi Integrity via iNOS-Dependent Mitochondrial Inhibition.
Across human, mouse, and rat β-cells, proinflammatory cytokines trigger Golgi compaction, ribbon loss, and fragmentation accompanied by altered cell-surface glycoproteins. iNOS-derived NO is necessary and sufficient for these β cell–specific Golgi changes via mitochondrial inhibition; human pancreatic samples show β cell–restricted Golgi alterations correlating with T1D progression.
Impact: Identifies an iNOS/NO–mitochondria–Golgi axis as a β cell–specific vulnerability explaining early secretory dysfunction in T1D, highlighting mechanistic targets for intervention.
Clinical Implications: Pharmacologic modulation of iNOS/NO signaling or mitochondrial resilience may preserve β-cell secretory architecture and function during the early inflammatory phase of T1D.
Key Findings
- Proinflammatory cytokines induce Golgi compaction, ribbon loss, and fragmentation in β-cells with persistent glycoprotein remodeling.
- iNOS-derived nitric oxide is necessary and sufficient to drive β cell–specific Golgi restructuring via mitochondrial inhibition.
- Human pancreatic tissue shows β cell–restricted Golgi alterations in autoantibody-positive and residual β-cells from T1D donors, correlating with disease progression.
Methodological Strengths
- Cross-species validation (human, mouse, rat) with mechanistic interrogation of iNOS/NO and mitochondria.
- Inclusion of human donor pancreatic tissues linking findings to disease progression.
Limitations
- Therapeutic modulation of the pathway was not tested in vivo.
- Longitudinal causality in humans cannot be established from cross-sectional tissue analysis.
Future Directions: Test iNOS/mitochondria-targeted interventions in preclinical T1D models to preserve Golgi integrity and secretion; develop biomarkers of β-cell Golgi stress.
UNLABELLED: Type 1 diabetes (T1D) is caused by the selective autoimmune ablation of pancreatic β-cells. Emerging evidence reveals β-cell secretory dysfunction arises early in T1D development and may contribute to diseases etiology; however, the underlying mechanisms are not well understood. Our data reveal that proinflammatory cytokines elicit a complex change in the β-cell's Golgi structure and function. The structural modifications include Golgi compaction and loss of the interconnecting ribbon resulting in Golgi fragmentation. We further show that Golgi structural alterations coincide with persistent altered cell surface glycoprotein composition. Our data demonstrate that inducible nitric oxide synthase (iNOS)-generated nitric oxide (NO) is necessary and sufficient for β-cell Golgi restructuring. Moreover, the unique sensitivity of the β-cell to NO-dependent mitochondrial inhibition results in β-cell-specific Golgi alterations that are absent in other cell types, including α-cells. Examination of human pancreas samples from autoantibody-positive and T1D donors with residual β-cells further revealed alterations in β-cell, but not α-cell, Golgi structure that correlate with T1D progression. Collectively, our studies provide critical clues as to how β-cell secretory functions are specifically impacted by cytokines and NO that may contribute to the development of β-cell autoantigens relevant to T1D. ARTICLE HIGHLIGHTS: Proinflammatory cytokines drive disruptions in Golgi structure and function in human, mouse, and rat β-cells. Golgi alterations result from inducible nitric oxide synthase (iNOS)- and nitric oxide (NO)-dependent inhibition of mitochondrial metabolism. α-Cell Golgi structure is insensitive to cytokine- and NO-mediated metabolic inhibition. Analysis of human donor tissue shows early Golgi alteration in β-cells from autoantibody-positive donors, which persists in residual β-cells from T1D donors.